Molecular Diagnostics

Ohana Laboratories


Ohana Laboratories advanced molecular diagnostic test panels empower clinicians to make decisions based on highly accurate and rapid identification of pathogens through DNA analysis of multiple pathogens at the same time. Because infections present with similar signs and symptoms, Ohana Labs infectious disease syndromic test panels help limit testing to the most common pathogens associated with a clinical syndrome by grouping probable pathogenic causes into one simple test. Rapid and highly accurate identification of the likely cause of Infection in one sample and one test streamlines the process and reduces the waiting period.

Respiratory Panel

The Ohana Respiratory panel tests for over twenty upper respiratory viral and bacterial pathogens commonly associated with respiratory infections, many of which present with nearly indistinguishable symptoms. Overall 97.1% Sensitivity and 99.3% Specificity identification of the most common bacterial or viral pathogens causing infections empowers healthcare providers to provide targeted treatment and avoid prescribing antibiotics for viral infections.

20 Respiratory Pathogens

Respiratory Panel

Viruses Tested:

  • Adenovirus
  • Coronavirus HKU1
  • Coronavirus NL63
  • Coronavirus 229E
  • Coronavirus OC43
  • Influenza A
  • Influenza A/H1
  • Influenza A/H1-2009
  • Human Rhinovirus
  • Enterovirus
  • Influenza A/H3
  • Influenza B
  • Parainfluenza Virus 1
  • Parainfluenza Virus 2
  • Parainfluenza Virus 3
  • Parainfluenza Virus 4
  • Respiratory Syncytial Virus
  • Human Metapneumovirus

Bacteria Tested:

  • Bordetella Pertussis
  • Mycoplasma Pneumoniae
  • Chlamydophila Pneumoniae
  • Bordetella parapertussis

Ohana testing keeps facilities ahead of the curve with coming surveys enforcing CMS final rule 483.80 that requires facilities to have:

  • A system for preventing, identifying, reporting, investigating, and controlling infections
  • A system of surveillance designed to identify possible communicable diseases or infections before they can spread to other persons in the facility
  • An antibiotic stewardship program that includes antibiotic use protocols and a system to monitor antibiotic use

Our program addresses this and reduces the risk of future survey infractions by:

  • Giving clinicians the evidence and 24-hour results to support their decisions
  • Reduced antibiotic usage
  • Assisting with antibiotic stewardship in the facility